Enrolment concludes in ONL Therapeutics’ Phase II GALAXY trial
ONL Therapeutics has concluded patient enrolment in its global Phase II GALAXY clinical trial assessing xelafaslatide for geographic atrophy (GA)…
ONL Therapeutics has concluded patient enrolment in its global Phase II GALAXY clinical trial assessing xelafaslatide for geographic atrophy (GA)…
MSD has discontinued its Phase III BELLWAVE-011 trial assessing nemtabrutinib (MK-1026) for leukaemia and other haematologic malignancies after an external…
Nuvation Bio has reported updated long-term follow-up findings from the Phase II J201 trial assessing safusidenib in patients with chemotherapy-…
Rein Therapeutics has reported preliminary blinded 12-week findings from the Phase II RENEW clinical study of its lead drug, LTI-03,…
Amylyx Pharmaceuticals has reported the data behind a Phase III trial win for its investigational glucagon-like peptide-1 (GLP-1) receptor antagonist…
Novo Nordisk has reported post hoc findings from the Phase III REDEFINE 1 trial evaluating its investigational combination therapy CagriSema…
Vivani Medical has reported positive topline findings from its Phase I SLIM-1 trial evaluating NPM-139, a subdermal semaglutide implant for…
Vasa Therapeutics has reported positive topline findings demonstrating clinical proof of concept for its lead therapy, VS-041, in a Phase…
Actinium Pharmaceuticals has begun patient enrolment in its Radiolabeled Antibody Distribution In Advanced Neoplasms with Zirconium-89 (RADIANZ) trial, an imaging…
Eli Lilly and Company has reported promising 52-week results from the Phase IIIb TOGETHER-PsA trial assessing Taltz (ixekizumab) alongside Zepbound…